WEIZMANN SCIENCE PARK, NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (TASE: KMDA), a bio-pharmaceutical company (www.kamada.com) engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has completed a Phase II Study with Aerosolized Alpha-1 Antitrypsin (AAT), delivered via an optimized eFlow platform nebulizer (PARI Pharma GmbH), in cystic fibrosis (CF). Preliminary results indicate that the product has an excellent safety profile; final data should be available by year-end 2008.
